Ontario Cancer Institute/Amgen Institute,
Department of Medical Biophysics, University of Toronto, Toronto,
Ontario M5G 2C1,1 Terry Fox Laboratory,
British Columbia Cancer Research Center, Vancouver, British Columbia
V5Z 1L3,2 and Department of Medicine,
University of British Columbia, Vancouver, British
Columbia,7 Canada; Center for
Radiological Research, College of Physicians and Surgeons, Columbia
University, New York, New York 100323;
Department of Biological Chemistry, UCLA School of Medicine and
Jonsson Comprehensive Cancer Center, Los Angeles, California
900954; Department of Pharmacology,
UNC-CH School of Medicine, Chapel Hill, North
Carolina6; and Amgen Inc., Thousand
Oaks, California 913205
 |
INTRODUCTION |
Most eukaryotic chromosome ends are
maintained by a ribonucleoprotein (RNP) complex called
telomerase. Telomerase is a reverse transcriptase that uses an
integral RNA component to catalyze the addition of telomeric repeats to
the 3' end of single-stranded telomeric DNA (8).
In many organisms, the telomerase complex is a large (750- to
1,000-kDa) RNP containing an integral RNA, a reverse transcriptase protein subunit, and several associated proteins. The
telomerase RNA component provides a template for telomere DNA
synthesis, and its essential role in telomerase activity,
telomere length maintenance, and chromosome stability has been
demonstrated in ciliates, yeast, and mice (2, 14-16, 29, 39,
42). The telomerase reverse transcriptase (TERT) was
first identified in the yeasts Saccharomyces cerevisiae
(EST2) and Schizosaccharomyces pombe
(trt1+) and the ciliate Euplotes
aediculatus (p123) (32, 36) and subsequently
in humans (hTERT) (12, 25, 34, 36, 38). Mutations
of conserved amino acids within the reverse transcriptase domain of
S. cerevisiae Est2 and in human TERT result in the loss of
telomerase activity (6, 12, 32, 38, 46). In rabbit reticulocyte lysates, human telomerase activity is
reconstituted by the addition of human TERT (hTERT) and the
telomerase RNA (1, 46).
In addition to the presumed core telomerase components,
consisting of the telomerase RNA and TERT, several proteins
associated with telomerase activity have also been identified.
In humans, the "foldosome" proteins hsp90 and p23 and three
telomerase RNA binding proteins, dyskerin, L22, and hStau, are
each associated with telomerase activity in cell extracts
(18, 28, 35). In S. cerevisiae, the Sm protein is
necessary for the stability of the yeast telomerase RNA
(44), while three other proteins, Est1, Est3, and Cdc13, are
dispensable for telomerase activity but are required for
telomere length maintenance (30, 33, 45). In the ciliate
Tetrahymena thermophila, two proteins that copurify with telomerase, p80 and p95 (4, 7, 10),
bind to telomerase RNA and telomeric DNA, although their
precise role in the Tetrahymena telomerase
complex is not yet clear (4, 7).
The mammalian homolog of p80, TEP1, is associated with
telomerase activity in human, mouse, and rat immortalized-cell
extracts (11, 37). The amino-terminal 900 amino acids
of TEP1, which contain the region homologous to
Tetrahymena p80, also interacted with telomerase RNA
in an in vivo RNA-protein interaction assay (11). Despite
its association with telomerase components, the role of TEP1 in
telomerase function is unknown. Recently, TEP1 has also been
identified as a component of a large cytoplasmic RNP termed the vault
particle (24). The genetic characterization of these
proteins is critical to our understanding of the complexity, composition, and regulation of telomerase in vivo. We utilized homologous recombination to disrupt the first mammalian
telomerase-associated protein to be identified, mTep1, in mice
and embryonic stem (ES) cells and analyzed the effects on
telomerase activity and telomere length maintenance.
 |
MATERIALS AND METHODS |
Construction of a murine Tep1 targeting vector.
To isolate murine Tep1 genomic fragments, a mouse
Tep1 BACMID genomic DNA clone was obtained from Genome
Systems Inc. (St. Louis, Mo.) and a full-length mTep1
cDNA probe was used. Two genomic KpnI/SphI
fragments (approximately 6.3 and 2.3 kb) of the mTep1 BACMID
DNA hybridized to a cDNA probe spanning a region containing the
first third of the mTep1 open reading frame. These fragments were
subcloned into pSPORT (Stratagene). A targeted construct was designed
to replace four exons of mTep1 with the neomycin resistance
gene. In brief, PCR primers (5'-CTCGAGGTTCGTAGGGTCAATGGTGTGTC-3' [sense] and 5'-GTCGACATTTCTGTGTTCAAGACAAATCAG-3'
[antisense]) were used to amplify a 3.7-kb long-arm fragment
from the 6.3-kb mTep1 genomic clone using the Expand long
template PCR system (Boehringer Mannheim). Similarly, an ~770-bp
short arm was amplified from the 2.3-kb mTep1 genomic clone
using the PCR primers 5'-TCTAGATAGGTGGCGTTGATCGGTGATCG-3' (sense) and 5'-GCGGCGGCAACCTTTTGAAGAACAACCAATG-3' (antisense).
Targeted disruption of the mTep1 gene in ES
cells.
The mTep1 targeting vector was linearized with
NotI at the short arm and electroporated into E14 ES cells
(derived from the R129J strain). After G418 selection (0.3 mg/ml),
homologous recombinants were identified by PCR and confirmed by
Southern blot analysis, following published protocols (9).
Primer TEP1-1, which is specific for the deleted portion of
mTep1, was used to detect the wild-type allele and primer
TEP1-2 was used to detect the mutant allele, while primer TEP1-3 was
used to detect both the wild-type and mutant alleles of
mTep1. PCR amplification was carried out with 30 cycles of
94°C for 1 min, 62°C for 1 min, and 72°C for 1 min. The sequences
of the above primers are as follows: TEP1-1,
5'-CCAGCAGTATGAGGGTCGTCAGTGG-3'; TEP1-2,
5'-GCTAAAGCGCATGCTCCAGAC-3'; and TEP1-3,
5'-CACATGCCTGTCTGGTTCTGTGGAG-3'.
Homologous recombination of the targeting vector with the endogenous
locus results in insertion of a novel SpeI site into the
mTep1 locus, thus allowing the targeted and wild-type
alleles to be distinguished by Southern analysis with a probe
corresponding to DNA just 3' to the short arm. Genomic DNA was digested
with SpeI, resolved on an agarose gel, transferred to a
membrane, and hybridized to the mTep1 genomic 3' flanking fragments.
Generation of mTep1-deficient mice and ES cells.
Chimeric mice were produced by microinjection of three independent
mTep1+/
ES cell clones into E3.5 C57BL/6J
blastocysts and transferred to ICR pseudopregnant foster mothers.
Chimeric males were mated with C57BL/6J females (Jackson Laboratory).
Germ line transmission of the mutant allele was confirmed by PCR and
Southern blot analysis of tail DNA from mice with an agouti coat color.
The mating strategy for the mTep1
/
mice was
the same as that used for the generation of the telomerase RNA-deficient mice (2). In brief, the first generation of
mTep1
/
homozgyous animals were referred to
as G1, and the subsequent generations (obtained by mating two
mTep1
/
animals of an equivalent generation
but derived from a different founder) were G2, G3, etc.
mTep1
/
ES cell clones were generated from
G418-resistant mTep1+/
ES cell clones by
culturing with an increased G418 concentration (4 mg/ml). ES cell
culture was carried out as previously described (9).
Cell lysate preparation and telomerase assays.
S-100
extracts from cultured cells and freshly dissected mouse tissues were
prepared as described previously (41). Cells lysed in a
buffer containing 0.5% CHAPS
{3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate} were
prepared as described elsewhere (26) (Intergen, Inc.). Telomerase activity was assayed using the telomeric repeat
amplification protocol (TRAP) assay following the manufacturer's
instructions (26) (Intergen, Inc.). The standard elongation
assay for telomerase activity was performed on S-100 extracts
after fractionation on DEAE-agarose columns as described previously
(5, 40).
Immunoprecipitation analysis of mTep1.
Immunoprecipitation
analysis using an affinity-purified anti-TEP1 polyclonal rabbit
antibody was performed as described previously (12). The
specificity of the TEP1 polyclonal antibody was confirmed by Western
analysis using cell extracts from human 293 cells overexpressing recombinant hTEP1 and using a glutathione transferase-mTEP1 recombinant purified fusion protein (12).
Telomere length measurements by FISH.
The average telomere
fluorescence at chromosome ends in splenocytes, thymocytes, and ES
cells was measured by using fluorescence in situ hybridization (FISH)
combined with flow cytometry (Flow-FISH) (43), with minor
modifications. A telomere-specific fluorescein isothiocyanate-conjugated (CCCTAA)3 peptide nucleic acid
probe (0.3 µg/ml) (Perseptive Biosystems) was employed. Telomere
fluorescence is expressed as molecules of equivalent soluble
fluorochrome (MESF) (13).
Metaphase spreads, FISH and image analyses of ES cells, and mouse
embryo fibroblast (MEF) cultures were performed as described elsewhere
(2, 47). The Cy-3-labeled (CCCTAA)3 peptide
nucleic acid was used as a probe.
 |
RESULTS |
Targeted disruption of mTep1 genes.
The
mTep1 targeting strategy was designed to disrupt a region of
mTep1 that is required for binding to the murine
telomerase RNA in a yeast three-hybrid interaction assay
(11) (Fig. 1A). Three separate
heterozygote mTep1 (mTep1+/
) ES
cell clones were used to generate mTep1+/
founder mice (data not shown). One of the
mTep1+/
ES cell clones was used to generate
three nullizygous mTep1 (mTep1
/
)
clones. Different mTep1+/
founders were bred
together to generate mTep1
/
mice (Fig. 1B).
The mTep1
/
mice were designated as
generation 1 (G1), and the progeny of G1 cousins were defined as G2, et
cetera, as described previously (2). Seven generations (to
G7) of mTep1
/
mice were fertile and showed
no obvious phenotypic defects compared to wild-type mice. Northern
analysis of poly(A)+ mRNA from several
mTep1
/
mouse tissues showed no detectable
transcripts upon hybridization to a full-length mTep1
cDNA probe (data not shown). Analysis of cell extracts
prepared from mTep1
/
G1 MEFs with an
affinity-purified anti-TEP1 rabbit polyclonal antiserum (spf2) revealed
no detectable mTep1 protein in lysates or anti-TEP1
immunoprecipitation from mTep1-deficient mouse tissues (Fig. 1C and data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Disruption of the murine Tep1 gene in ES
cells and mice. (A) Schematic representation of homologous
recombination of the targeting vector with the endogenous locus.
Insertion of a new Spe1 site into the targeted locus allows
the targeted and wild-type alleles to be distinguished by Southern blot
analysis with the indicated 3' flanking probe. S, SpeI; N,
Not1. (B) Detection of targeted and wild-type
mTep1 alleles by Southern blot analysis of DNA from G1 mice.
DNA was digested with SpeI and hybridized with the probe
shown in panel A. The 5.1-kb SpeI fragment corresponding to
the wild-type allele is decreased to 1.6 kb upon disruption of the
locus by integration of the Neor gene. (C) Immunoblot of
MEF extracts probed with an anti-TEP1 antibody (12). The
position of the mTep1 protein is indicated. The first lane contains
human 293 cell lysate transfected with a recombinant hTEP1 plasmid
(293-hTEP1). The protein species below the 85-kDa protein marker in
each immunoprecipitate is not specific to anti-TEP1 antibody.
|
|
mTep1 is not essential for telomerase catalysis in
vivo.
To determine the role of mTep1 in telomerase
catalysis, we examined mTep1-deficient ES cells, MEF
cultures derived from G1 mTep1
/
embryos, and
several tissues from mTep1
/
mice (up to G3)
for telomerase activity. In both the conventional telomerase elongation assay and the PCR-based
telomerase assay (TRAP) (26), all three
independently derived mTep1
/
ES cell clones
possessed levels of telomerase activity similar to those in the
mTep1+/
clone and the parental line (data not
shown). We also tested whether telomerase activity was altered
in tissues from mTep1
/
mice. Telomerase
activity was not significantly altered in testes, liver, kidney, lung,
or thymus tissue from mTep1
/
mice compared
to wild-type mouse tissues (Fig. 2A and
Table 1). Subsequent analysis of several
tissues that normally lack telomerase activity, including
brain, skin, heart, and spleen (2, 41), revealed no
reactivation of telomerase activity in these tissues from
mTep1
/
mice (Table 1 and data not shown). In
MEFs derived from G1 mTep1
/
embryos, there
was also no significant change in telomerase activity compared
to that in the mTep1+/
and wild-type MEFs
(Table 1 and data not shown). In the conventional telomerase assay, we did not detect any changes in
telomerase activity levels in liver or testis extracts
from mTep1
/
mice (Fig. 2B).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
Telomerase activity of mTep1-deficient
tissues. (A) TRAP was performed for 25 cycles on testis tissue extracts
of the indicated genotype. R, RNase A treatment of the sample. An
internal PCR standard for TRAP is shown at bottom right. The amounts of
testis extract used was as follows: 4 µg of extract plus RNase A
(wild-type testis), or 4, 2, 1, and 0.5 µg of testis extract. (B) The
conventional telomerase elongation assay was performed on
murine liver and testes. A telomerase-positive human cell
extract (Raji) is shown as a positive control. The arrow indicates the
position of telomerase elongation products from mouse tissue
extract, which were sensitive to RNase A treatment (R). The amount of
extract used for each sample was 15 or 7.5 µg.
|
|
The role of mTep1 in telomere length regulation in vivo.
Mice
and ES cells disrupted in the telomerase RNA component lack
telomerase activity and undergo telomere attrition in vivo (2, 16, 29, 39). In S. cerevisiae,
EST1, EST3, and CDC13 are not required
for telomerase activity (31); however, mutation or
disruption of these genes results in progressive telomere loss (30, 31). To determine whether loss of mTep1
could be essential for telomere length maintenance, we analyzed
telomere length in mTep1-deficient mice and ES cells.
To examine telomere length in a total cell population, we used a
quantitative method called Flow-FISH (43). We observed that
none of the mTep1+/
and three independent
mTep1
/
ES cell clones showed significant
changes in average telomere fluorescence intensity, regardless of
increasing population doublings, compared to early or late passages of
wild-type cells (Fig. 3A). Thymocytes and
splenocytes derived from different generations of
mTep1-deficient mice (G1 to G7) also yielded very similar
measurements of relative telomere lengths that were comparable to those
of the G1 mTep1 heterozygote control (Fig. 3B and data not
shown). The overall distribution of telomere signal fluorescence in the G1 and G7 samples was similar to that in the heterozygous
mTep1 control (data not shown). Similarly, FISH analysis of
metaphase chromosome preparations from mTep1-deficient MEFs
showed no significant change in telomere signal intensity or
chromosomal aberrations compared to the wild-type MEFs (Fig.
4). We therefore conclude that disruption
of mTep1 had no effect on either the distribution or mean
length of telomeres.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Relative telomere lengths in ES cells and in splenocytes
and thymocytes derived from mouse tissues, determined by Flow-FISH. (A)
Average telomere fluorescence in early (p1) and later (p10 and p20)
passages of ES cells, including wild type,
mTep1+/ , and three
mTep1 / clones. Each MESF value represents
the results for one individual ES clone at the indicated passage;
hence, there are no error bars. (B) Average telomere fluorescence in
splenocytes and thymocytes derived from early and late generations (G1
through G7) of mTep1 / mice. In each set,
data were pooled from at least five mice (error bars represent standard
deviations).
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
FISH analysis of metaphase preparations of primary MEFs
derived from G1 mTep1+/+ (A) or G5
mTep1 / embryos (B). No significant changes
in telomere signal intensity or chromosomal aberrations were detected
in the G5 mTep1 / embryos.
|
|
 |
DISCUSSION |
In mammals, the first genetic evidence for the essential role of
telomerase activity in telomere length maintenance was
elegantly demonstrated in mice lacking the telomerase RNA
component (2, 14-16, 29, 39, 42). In this study, we have
used a genetic approach to examine the role of the first identified
mammalian telomerase-associated protein, mTep1, in
telomerase catalysis and telomere length regulation in vivo.
Despite the fact that TEP1 is associated with the telomerase
RNA and the telomerase catalytic subunit TERT in cell extracts from immortalized human, mouse, and rat cells,
mTep1-deficient mice show no significant alteration in
telomerase activity or telomere length. These results indicate
that mTep1 is not essential for the catalytic activity of the
telomerase complex, at least as measured by the in vitro
elongation assay, and that as observed when deleted alone, mTep1 is not
required for telomere length maintenance. These results are consistent
with our previous finding from an in vitro assay that the
reconstitution of human telomerase activity does not require
the addition of hTEP1 (1).
Several possibilities could account for the absence of a
telomerase-associated phenotype in
mTep1
/
mice. Since mTep1 is associated with
telomerase activity in immortalized cells, it is possible that
it plays a specific role in the function of telomerase in
immortalized cells but not in normal cells (11). Another
possibility is that if TEP1 is associated with only a fraction of the
total telomerase activity in vivo, its disruption might have no
overt phenotypic consequences. A substoichiometric association of TEP1
with telomerase activity is suggested by the observation that
antibodies against TEP1, hStau, and L22 are each able to
immunoprecipitate telomerase activity, but not each other, from
human immortalized cell extracts (28). Alternatively, other telomerase RNA binding proteins may share a redundant role with mTep1 in telomerase function. In Tetrahymena, both
p80 and p95 synergistically bind to the telomerase RNA (4,
7). A mammalian homolog of p95 has not yet been identified. In
mammals, two additional telomerase RNA binding proteins, L22
and hStau, were cloned using a yeast three-hybrid screen
(28). These proteins are each associated with
telomerase activity and hTERT, and yet there is no evidence of
a direct association with each other or with TEP1 (28).
Whether separate telomerase complexes containing distinct
telomerase RNA binding proteins share overlapping
functions in vivo has yet to be determined. Indirect immunofluorescence
analysis of TEP1 and TERT will be instrumental in demonstrating whether
TEP1 indeed colocalizes with a subset of hTERT in intact cells.
Not all telomerase-associated proteins appear to be restricted
to the telomerase complex. At least some fraction of human telomerase activity is associated with p23 and Hsp90, two
components of the ubiquitous foldosome which facilitate assembly of the
active telomerase complex in rabbit reticulocyte lysates
(18). TEP1 is expressed in many tissues, including those
that lack telomerase activity, suggesting that TEP1 may be
important for other cellular functions. In support of this notion, TEP1
has also recently been discovered to be an integral component of a
large cytoplasmic (13-MDa) RNP complex referred to as the vault
particle (24). Vault particles have been isolated from a
number of organisms and appear to be ubiquitous among eukaryotes
(19). Although the function of the vault particle is
unknown, several recent reports have implicated the particle in
intracellular transport (3, 17, 20, 27). Purified vaults
display an eight-fold, barrel-like symmetry and contain at least three
components in addition to TEP1, including the 104-kDa major vault
protein MVP (21), a 193-kDa poly(ADP-ribosyl)
polymerase called VPARP (23), and a small RNA called
vRNA (20, 22). TEP1, but not telomerase activity,
copurifies with the vault particle, and several vRNAs specifically
interact with TEP1 in the yeast RNA-protein interaction assay
(24). The so-called subunit sharing of the TEP1 protein between two seemingly unrelated RNPs suggests that TEP1 may play a more
general role in RNP structure, function, or assembly. It is thus
possible that TEP1 is a part of other RNPs in addition to the vault and
telomerase complexes. Le and colleagues have also proposed that
the telomerase RNA binding proteins hStau and L22 might be
involved in aspects of RNA processing or RNP assembly that are not
limited to telomerase (28). While the absence of a
direct role for telomerase is confounding, the generation of mTep1-deficient mice is a first step toward the genetic
dissection of the relationship between telomerase and the
assembly and regulation of other cellular RNP complexes. We are
currently examining mTep1-deficient mice for the role of
TEP1 in vaults and for the possible involvement of TEP1 in other RNPs.
In addition, the generation of mice deficient in other
telomerase-associated components will enable us to ascertain whether TEP1 is genetically redundant with other telomerase RNA binding proteins for telomerase function in vivo.
We thank Carol Greider, Siyuan Le, Tak Mak, and members of the
Harrington laboratory for critical comments and discussion; Denis
Bouchard and Mark Ungrin for assistance with Flow-FISH; and Natalie
Erdmann for technical assistance.
Y.L. is a research fellow of the National Cancer Institute of Canada
and is supported with funds provided by the Terry Fox Run. L.H.
acknowledges the support of the Medical Research Council and the
National Institute of Health (no. AG8422117).
| 1.
|
Beattie, T. L.,
W. Zhou,
M. O. Robinson, and L. Harrington.
1998.
Reconstitution of human telomerase activity in vitro.
Curr. Biol.
8:177-180[CrossRef][Medline].
|
| 2.
|
Blasco, M. A.,
H. W. Lee,
M. P. Hande,
E. Samper,
P. M. Lansdorp,
R. A. DePinho, and C. W. Greider.
1997.
Telomere shortening and tumor formation by mouse cells lacking telomerase RNA.
Cell
91:25-34[CrossRef][Medline].
|
| 3.
|
Chugani, D. C.,
L. H. Rome, and N. L. Kedersha.
1993.
Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex.
J. Cell Sci.
106:23-29[Abstract].
|
| 4.
|
Collins, K.,
R. Kobayashi, and C. W. Greider.
1995.
Purification of Tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme.
Cell
81:677-686[CrossRef][Medline].
|
| 5.
|
Counter, C. M.,
A. A. Avilion,
C. E. LeFeuvre,
N. G. Stewart,
C. W. Greider,
C. B. Harley, and S. Bacchetti.
1992.
Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity.
EMBO J.
11:1921-1929[Medline].
|
| 6.
|
Counter, C. M.,
M. Meyerson,
E. N. Eaton, and R. A. Weinberg.
1997.
The catalytic subunit of yeast telomerase.
Proc. Natl. Acad. Sci. USA
94:9202-9207[Abstract/Free Full Text].
|
| 7.
|
Gandhi, L., and K. Collins.
1998.
Interaction of recombinant Tetrahymena telomerase proteins p80 and p95 with telomerase RNA and telomeric DNA substrates.
Genes Dev.
12:721-733[Abstract/Free Full Text].
|
| 8.
|
Greider, C. W.
1996.
Telomere length regulation.
Annu. Rev. Biochem.
65:337-365[CrossRef][Medline].
|
| 9.
|
Hakem, R.,
J. L. de la Pompa,
C. Sirard,
R. Mo,
M. Woo,
A. Hakem,
A. Wakeham,
J. Potter,
A. Reitmair,
F. Billia,
E. Firpo,
C. C. Hui,
J. Roberts,
J. Rossant, and T. W. Mak.
1996.
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.
Cell
85:1009-1023[CrossRef][Medline].
|
| 10.
|
Harrington, L.,
C. Hull,
J. Crittenden, and C. Greider.
1995.
Gel shift and UV cross-linking analysis of Tetrahymena telomerase.
J. Biol. Chem.
270:8893-8901[Abstract/Free Full Text].
|
| 11.
|
Harrington, L.,
T. McPhail,
V. Mar,
W. Zhou,
R. Oulton,
M. B. Bass,
I. Arruda, and M. O. Robinson.
1997.
A mammalian telomerase-associated protein.
Science
275:973-977[Abstract/Free Full Text].
|
| 12.
|
Harrington, L.,
W. Zhou,
T. McPhail,
R. Oulton,
D. S. Yeung,
V. Mar,
M. B. Bass, and M. O. Robinson.
1997.
Human telomerase contains evolutionarily conserved catalytic and structural subunits.
Genes Dev.
11:3109-3115[Abstract/Free Full Text].
|
| 13.
|
Henderson, L. O.,
G. E. Marti,
A. Gaigalas,
W. H. Hannon, and R. F. Vogt, Jr.
1998.
Terminology and nomenclature for standardization in quantitative fluorescence cytometry.
Cytometry
33:97-105[CrossRef][Medline].
|
| 14.
|
Herrera, E.,
A. C. Martinez, and M. A. Blasco.
2000.
Impaired germinal center reaction in mice with short telomeres.
EMBO J.
19:472-481[CrossRef][Medline].
|
| 15.
|
Herrera, E.,
E. Samper, and M. A. Blasco.
1999.
Telomere shortening in mTR / embryos is associated with failure to close the neural tube.
EMBO J.
18:1172-1181[CrossRef][Medline].
|
| 16.
|
Herrera, E.,
E. Samper,
J. Martin-Caballero,
J. M. Flores,
H. W. Lee, and M. A. Blasco.
1999.
Disease states associated with telomerase deficiency appear earlier in mice with short telomeres.
EMBO J.
18:2950-2960[CrossRef][Medline].
|
| 17.
|
Herrmann, C.,
E. Golkaramnay,
E. Inman,
L. Rome, and W. Volknandt.
1999.
Recombinant major vault protein is targeted to neuritic tips of PC12 cells.
J. Cell Biol.
144:1163-1172[Abstract/Free Full Text].
|
| 18.
|
Holt, S. E.,
D. L. Aisner,
J. Baur,
V. M. Tesmer,
M. Dy,
M. Ouellette,
J. B. Trager,
G. B. Morin,
D. O. Toft,
J. W. Shay,
W. E. Wright, and M. A. White.
1999.
Functional requirement of p23 and Hsp90 in telomerase complexes.
Genes Dev.
13:817-826[Abstract/Free Full Text].
|
| 19.
|
Kedersha, N. L.,
M. C. Miquel,
D. Bittner, and L. H. Rome.
1990.
Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes.
J. Cell Biol.
110:895-901[Abstract/Free Full Text].
|
| 20.
|
Kickhoefer, V. A.,
K. S. Rajavel,
G. L. Scheffer,
W. S. Dalton,
R. J. Scheper, and L. H. Rome.
1998.
Vaults are up-regulated in multidrug-resistant cancer cell lines.
J. Biol. Chem.
273:8971-8974[Abstract/Free Full Text].
|
| 21.
|
Kickhoefer, V. A., and L. H. Rome.
1994.
The sequence of a cDNA encoding the major vault protein from Rattus norvegicus.
Gene
151:257-260[CrossRef][Medline].
|
| 22.
|
Kickhoefer, V. A.,
R. P. Searles,
N. L. Kedersha,
M. E. Garber,
D. L. Johnson, and L. H. Rome.
1993.
Vault ribonucleoprotein particles from rat and bullfrog contain a related small RNA that is transcribed by RNA polymerase III.
J. Biol. Chem.
268:7868-7873[Abstract/Free Full Text].
|
| 23.
|
Kickhoefer, V. A.,
A. C. Siva,
N. L. Kedersha,
E. M. Inman,
C. Ruland,
M. Streuli, and L. H. Rome.
1999.
The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase.
J. Cell Biol.
146:917-928[Abstract/Free Full Text].
|
| 24.
|
Kickhoefer, V. A.,
A. G. Stephen,
L. Harrington,
M. O. Robinson, and L. H. Rome.
1999.
Vaults and telomerase share a common subunit, TEP1.
J. Biol. Chem.
274:32712-32717[Abstract/Free Full Text].
|
| 25.
|
Kilian, A.,
D. D. Bowtell,
H. E. Abud,
G. R. Hime,
D. J. Venter,
P. K. Keese,
E. L. Duncan,
R. R. Reddel, and R. A. Jefferson.
1997.
Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types.
Hum. Mol. Genet.
6:2011-2019[Abstract/Free Full Text].
|
| 26.
|
Kim, N. W.,
M. A. Piatyszek,
K. R. Prowse,
C. B. Harley,
M. D. West,
P. L. Ho,
G. M. Coviello,
W. E. Wright,
S. L. Weinrich, and J. W. Shay.
1994.
Specific association of human telomerase activity with immortal cells and cancer.
Science
266:2011-2015[Abstract/Free Full Text].
|
| 27.
|
Kong, L. B.,
A. C. Siva,
L. H. Rome, and P. L. Stewart.
1999.
Structure of the vault, a ubiquitous cellular component.
Structure
7:371-379[Medline].
|
| 28.
|
Le, S.,
R. Sternglanz, and C. W. Greider.
2000.
Identification of two RNA-binding proteins associated with human telomerase RNA.
Mol. Biol. Cell
11:999-1010[Abstract/Free Full Text].
|
| 29.
|
Lee, H. W.,
M. A. Blasco,
G. J. Gottlieb,
J. W. Horner, II,
C. W. Greider, and R. A. DePinho.
1998.
Essential role of mouse telomerase in highly proliferative organs.
Nature
392:569-574[CrossRef][Medline].
|
| 30.
|
Lendvay, T. S.,
D. K. Morris,
J. Sah,
B. Balasubramanian, and V. Lundblad.
1996.
Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes.
Genetics
144:1399-1412[Abstract].
|
| 31.
|
Lingner, J.,
T. R. Cech,
T. R. Hughes, and V. Lundblad.
1997.
Three Ever Shorter Telomere (EST) genes are dispensable for in vitro yeast telomerase activity.
Proc. Natl. Acad. Sci. USA
94:11190-11195[Abstract/Free Full Text].
|
| 32.
|
Lingner, J.,
T. R. Hughes,
A. Shevchenko,
M. Mann,
V. Lundblad, and T. R. Cech.
1997.
Reverse transcriptase motifs in the catalytic subunit of telomerase.
Science
276:561-567[Abstract/Free Full Text].
|
| 33.
|
Lundblad, V., and J. W. Szostak.
1989.
A mutant with a defect in telomere elongation leads to senescence in yeast.
Cell
57:633-643[CrossRef][Medline].
|
| 34.
|
Meyerson, M.,
C. M. Counter,
E. N. Eaton,
L. W. Ellisen,
P. Steiner,
S. D. Caddle,
L. Ziaugra,
R. L. Beijersbergen,
M. J. Davidoff,
Q. Liu,
S. Bacchetti,
D. A. Haber, and R. A. Weinberg.
1997.
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.
Cell
90:785-795[CrossRef][Medline].
|
| 35.
|
Mitchell, J. R.,
E. Wood, and K. Collins.
1999.
A telomerase component is defective in the human disease dyskeratosis congenita.
Nature
402:551-555[CrossRef][Medline].
|
| 36.
|
Nakamura, T. M.,
G. B. Morin,
K. B. Chapman,
S. L. Weinrich,
W. H. Andrews,
J. Lingner,
C. B. Harley, and T. R. Cech.
1997.
Telomerase catalytic subunit homologs from fission yeast and human.
Science
277:955-959[Abstract/Free Full Text].
|
| 37.
|
Nakayama, J.,
M. Saito,
H. Nakamura,
A. Matsuura, and F. Ishikawa.
1997.
TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family.
Cell
88:875-884[CrossRef][Medline].
|
| 38.
|
Nakayama, J.,
H. Tahara,
E. Tahara,
M. Saito,
K. Ito,
H. Nakamura,
T. Nakanishi,
T. Ide, and F. Ishikawa.
1998.
Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas.
Nat. Genet.
18:65-68[CrossRef][Medline].
|
| 39.
|
Niida, H.,
T. Matsumoto,
H. Satoh,
M. Shiwa,
Y. Tokutake,
Y. Furuichi, and Y. Shinkai.
1998.
Severe growth defect in mouse cells lacking the telomerase RNA component.
Nat. Genet.
19:203-206[CrossRef][Medline].
|
| 40.
|
Prowse, K. R.,
A. A. Avilion, and C. W. Greider.
1993.
Identification of a nonprocessive telomerase activity from mouse cells.
Proc. Natl. Acad. Sci. USA
90:1493-1497[Abstract/Free Full Text].
|
| 41.
|
Prowse, K. R., and C. W. Greider.
1995.
Developmental and tissue-specific regulation of mouse telomerase and telomere length.
Proc. Natl. Acad. Sci. USA
92:4818-4822[Abstract/Free Full Text].
|
| 42.
|
Rudolph, K. L.,
S. Chang,
H. W. Lee,
M. Blasco,
G. J. Gottlieb,
C. Greider, and R. A. DePinho.
1999.
Longevity, stress response, and cancer in aging telomerase-deficient mice.
Cell
96:701-712[CrossRef][Medline].
|
| 43.
|
Rufer, N.,
W. Dragowska,
G. Thornbury,
E. Roosnek, and P. M. Lansdorp.
1998.
Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry.
Nat. Biotechnol.
16:743-747[CrossRef][Medline].
|
| 44.
|
Seto, A. G.,
A. J. Zaug,
S. G. Sobel,
S. L. Wolin, and T. R. Cech.
1999.
Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle.
Nature
401:177-180[CrossRef][Medline].
|
| 45.
|
Singer, M. S., and D. E. Gottschling.
1994.
TLC1: template RNA component of Saccharomyces cerevisiae telomerase.
Science
266:404-409[Abstract/Free Full Text].
|
| 46.
|
Weinrich, S. L.,
R. Pruzan,
L. Ma,
M. Ouellette,
V. M. Tesmer,
S. E. Holt,
A. G. Bodnar,
S. Lichtsteiner,
N. W. Kim,
J. B. Trager,
R. D. Taylor,
R. Carlos,
W. H. Andrews,
W. E. Wright,
J. W. Shay,
C. B. Harley, and G. B. Morin.
1997.
Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT.
Nat. Genet.
17:498-502[CrossRef][Medline].
|
| 47.
|
Zijlmans, J. M.,
U. M. Martens,
S. S. Poon,
A. K. Raap,
H. J. Tanke,
R. K. Ward, and P. M. Lansdorp.
1997.
Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats.
Proc. Natl. Acad. Sci. USA
94:7423-7428[Abstract/Free Full Text].
|